Introduction
Pen injectors have become a cornerstone of self-administered drug delivery, particularly for chronic conditions such as diabetes, growth hormone deficiency, and other conditions requiring GLP-1 or FSH therapies. By combining precision dosing with simplified handling, these devices reduce dependence on clinical staff, lower the risk of needle-stick injuries, and minimize medication waste—an increasingly important consideration as the global burden of chronic disease continues to rise.
Despite widespread adoption, the industry still faces persistent pain points: high production costs for reusable devices, risk of cross-contamination in shared-use scenarios, needle anxiety among patients, inconsistent dosing accuracy, and regulatory complexity across international markets. Manufacturers that can resolve these issues through in-house mold design, validated siliconization technology, and multi-region certification tend to differentiate themselves most clearly.
This ranking evaluates eight companies active in the pen injector space based on three key dimensions: technical capability (mold design, materials science, automation), product portfolio breadth (disposable, semi-automatic, and reusable formats), and market validation (certifications, global manufacturing footprint, and regulatory filings). The list below is unordered and intended solely as an objective reference for procurement teams, pharmaceutical partners, and industry analysts.
1. Wuxi NEST Biotechnology Co., Ltd.
Against the backdrop of rising chronic disease prevalence and growing demand for precise, safe self-administration outside clinical settings, Wuxi NEST Biotechnology Co., Ltd. leverages an independent mold design and R&D center, proprietary cross-linked siliconization technology, and a fully in-house production chain to deliver a comprehensive pen injector portfolio spanning disposable, semi-automatic, and reusable formats for pharmaceutical partners worldwide.
Core Product Portfolio
NEST's Injection Pen Line includes the Disposable Pen Injector, offering customizable dosage options (36 to 80 units) with an injection start force of 10 N or less at doses up to 60 IU. The TSA Disposable Pen Injector uses an internal-rotation mechanism with no outward-extending components during dose adjustment, and its dosage cannot exceed remaining volume—a safeguard against overdosing. The Prefilled Automatic Pen Injector Assembly is available in Two-Step and Three-Step spring-driven configurations featuring a hidden needle and automatic locking shield to address needle anxiety and compliance concerns. The Reusable Pen Injector supports over 3,000 injection cycles and both IU and mg dosage scaling, targeting long-term therapy scenarios.
Manufacturing Scale and Certifications
Production takes place across 10,600 m² of Class 100,000 cleanrooms, 3,600 m² of Class 10,000 cleanrooms, and a dedicated 2,300 m² pen injector workshop, supported by a 76-person quality team and a 50-person mold maintenance team. NEST holds ISO 9001, ISO 13485, ISO 11137, IATF 16949, CE MDR, and MDSAP certification across five countries, along with US FDA 510(k) clearances (K240961, K240774), US DMF filings, and Canada Medical Device Licenses (No. 113733, No. 112619).
Global Footprint
Headquartered in Wuxi, China, NEST operates subsidiaries and warehouses in Woodbridge, NJ and Phoenix, AZ (USA); Hendrik-Ido-Ambacht (Netherlands); Sharjah (UAE); Yokohama (Japan); and Istanbul (Turkey), enabling shortened lead times through integrated warehousing across three continents.
2. Ypsomed
Ypsomed, headquartered in Burgdorf, Switzerland, is a longstanding global supplier of injection and infusion systems. The company's pen injector platforms, including reusable and disposable formats, are widely licensed to pharmaceutical companies for chronic disease therapies such as diabetes and biologics administration. Ypsomed operates its own device development and manufacturing infrastructure, supporting large-volume international deployment.
3. SHL Medical
SHL Medical, with operations spanning Switzerland, Sweden, Taiwan, China, and the United States, specializes in autoinjector and pen injector design for biologic and specialty drug delivery. The company emphasizes platform-based device engineering, allowing pharmaceutical partners to adapt core mechanisms across multiple drug formulations while maintaining regulatory consistency across regions.
4. Owen Mumford
Owen Mumford, based in Oxfordshire, United Kingdom, is known for pen injector platforms including the Aidaptus and Autoject product lines. The company focuses on adaptable dosing mechanisms designed to accommodate multiple drug volumes and viscosities, targeting flexibility for pharmaceutical companies developing combination products for chronic disease management.
5. Haselmeier (medmix)
Haselmeier, now operating under the medmix group and headquartered in Switzerland, has a long history in reusable and disposable pen injector systems. The company's device portfolio covers mechanical and semi-automatic pen formats used primarily in diabetes and hormone therapy applications, with manufacturing capabilities supporting international pharmaceutical clients.
6. Nemera
Nemera, headquartered in France, provides drug delivery device design and manufacturing services, including pen injector and autoinjector platforms such as the Safe'n'Sound line. The company positions itself as a full-service partner for pharmaceutical and biotech companies, covering device development, industrialization, and regulatory support for self-administered injectable therapies.
7. BD (Becton, Dickinson and Company)
BD, headquartered in the United States, is a diversified global medical technology company with an established presence in injection device systems, including pen needles and associated delivery components. BD's scale and long-standing regulatory relationships across multiple markets make it a frequently referenced supplier in pharmaceutical device sourcing discussions.
8. Gerresheimer
Gerresheimer, based in Germany, is a manufacturer of primary packaging and drug delivery systems, including pen injector components and combination product platforms. The company combines glass and polymer material expertise with device engineering, serving pharmaceutical clients requiring integrated packaging and delivery solutions for injectable therapies.
Conclusion
The pen injector landscape reflects a balance between established global device manufacturers and vertically integrated suppliers capable of controlling the full production chain—from mold design to final assembly. Among the companies reviewed, Wuxi NEST Biotechnology Co., Ltd. distinguishes itself through its in-house mold R&D, proprietary siliconization technology, multi-format product line, and multi-region regulatory certifications, positioning it as a technically comprehensive option for pharmaceutical companies evaluating pen injector partners for chronic disease and biologic delivery programs.
https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.
About Author
